Spiramycin

Research use only, not for human use.

A macrolide antibiotic produced by Streptomyces ambofaciens.

A macrolide antibiotic produced by Streptomyces ambofaciens. The drug is effective against gram-positive aerobic pathogens, N. gonorrhoeae, and staphylococci. It is used to treat infections caused by bacteria and Toxoplasma gondii. (In Vitro):Spiramycin (24 hours; 1-1000 μM; T. gondii infected HeLa cells and HeLa cells) treatment reduces the cytotoxicity, and shows anti-Toxoplasma gondii activity, with IC50 values of 189 μM for HeLa cells; and 262 μM for T. gondii-infected HeLa cells.(In Vivo):Spiramycin (100 mg/kg; intraperitoneal injection; every day; for 4 days; female KM mice) treatment reduces the number of tachyzoites, and reduces hepatotoxicity and significantly enhances antioxidative effects. Spiramycin treatment also decreases in the degree of granulomatous inflammation in the liver.

Spiramycin (24 hours; 1-1000 μM; T. gondii infected HeLa cells and HeLa cells) treatment reduces the cytotoxicity, and shows anti-Toxoplasma gondii activity, with IC50 values of 189 μM for HeLa cells; and 262 μM for T. gondii-infected HeLa cells. Cell Cytotoxicity Assay Cell Line:T. gondii infected HeLa cells and HeLa cells Concentration:1-1000 μM Incubation Time:24 hours Result:Reduced the cytotoxicity.

Spiramycin (100 mg/kg; intraperitoneal injection; every day; for 4 days; female KM mice) treatment reduces the number of tachyzoites, and reduces hepatotoxicity and significantly enhances antioxidative effects. Spiramycin treatment also decreases in the degree of granulomatous inflammation in the liver. Animal Model:36 female KM mice with T.gondiiDosage:100 mg/kgAdministration:Intraperitoneal injection; every day; for 4 daysResult:The number of tachyzoites was significantly reduced. Reduced hepatotoxicity and significantly enhanced antioxidative effects. Granuloma and cyst formation were inhibitied.

Formacidine | NSC 55926 | Rovamycine

Others

Other Targets

Others

Other Indications

——

8025-81-8

843.07

C43H74N2O14

>98% (HPLC)

Ethanol: 100 mg/mL (118.61 mM); DMSO: 100 mg/mL (118.61 mM)

C[C@@H]1C/C=C/C=C/[C@@H]([C@@H](C[C@@H]([C@@H]([C@H]([C@@H](CC(=O)O1)O)OC)OC2C(C(C(C(O2)C)OC3CC(C(C(O3)C)O)(C)O)N(C)C)O)CC=O)C)OC4CCC(C(O4)C)N(C)C

——

(-20℃)

With Ice Pack

≥ 2 years